CytoMed Therapeutics Ltd
GDTC evidence brief
What we can confirm
- BioSniper Score:
- 9.5 / 10
- Market Cap:
- $9.3M
What it means
What to watch
Prepared research question
What matters most for GDTC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GDTC
CytoMed Therapeutics Ltd (GDTC) is a clinical-stage biopharmaceutical company headquartered in Singapore, focused on developing allogeneic immune cell-based cancer therapies and mesenchymal stem cell (MSC) treatments for degenerative diseases, with production facilities in Malaysia.
Key risk: Cash runway risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$9.3M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
CytoMed Therapeutics Ltd (GDTC) is a clinical-stage biopharmaceutical company headquartered in Singapore, focused on developing allogeneic immune cell-based cancer therapies and mesenchymal stem cell (MSC) treatments for degenerative diseases, with production facilities in Malaysia.
- Cash & equivalents of $1.6M and shareholders' equity of $5.1M as of 2025-12-31 [sec].
- Lead product candidate is CTM-N2D, with CTM-GDT based on the same core technology [sec · filed 2025-04-28].
- Conducts business primarily through Malaysian subsidiaries CytoMed Malaysia and IPSC Depository, with a cGMP facility in Johor, Malaysia built to PIC/S GMP standards [sec · filed 2026-03-31].
- Accumulated losses of S$14.85 million and S$18.83 million as of the latest annual report [sec · filed 2026-03-31].
- The ANGELICA Trial is conducted jointly with National University Hospital Singapore, and either party may terminate with 30 days' notice [sec · filed 2026-03-31].
What works
- Operates a cGMP facility in Johor, Malaysia built to international PIC/S GMP standards, supporting cell therapy manufacturing [sec · filed 2026-03-31].
- Has established collaborations with Singapore's A*STAR and National University Hospital Singapore, leveraging local research infrastructure [sec · filed 2026-03-31].
- Focuses on allogeneic (off-the-shelf) cell therapies, which could enable scalable and potentially more affordable cancer treatments [sec · filed 2026-03-31].
What to weigh
- Cash & equivalents of only $1.6M as of 2025-12-31, with accumulated losses of S$14.85M and S$18.83M, and expects increasing losses for the foreseeable future [sec · filed 2026-03-31].
- The ANGELICA Trial agreement allows either party to terminate with 30 days' notice, and the hospital can terminate immediately if safety concerns arise [sec · filed 2026-03-31].
- All product candidates (CTM-N2D, iPSC-gdNKT, CTM-GDT, CTM-MSC, CTM-NK) are in early stages with no assurance of safety, efficacy, or regulatory approval [sec · filed 2026-03-31].
- Requires additional capital; if unavailable, may have to discontinue operations, and if obtained, may cause dilution or loss of rights to product candidates [sec · filed 2025-04-28].
From the filings
Quoted directly from source documents.
Accumulated losses
“accumulated losses of S$14.85 million and S$18.83 million, respectively”
SEC filings · March 31, 2026
Termination clause for ANGELICA Trial
“Either party may terminate the Clinical Study Agreement at any time upon providing at least thirty (30) days' prior written notice to the other party.”
SEC filings · March 31, 2026
Reliance on lead product candidate
“CTM-N2D is our lead product candidate and CTM-GDT is based on the same core proprietary technology”
SEC filings · April 28, 2025
Risks & what to watch (4)›
Key risks
- Cash runway risk — Only $1.6M cash as of 2025-12-31 with increasing losses; may need additional financing to continue operations [sec · filed 2026-03-31].
- Clinical trial termination risk — ANGELICA Trial partner can terminate with 30 days' notice or immediately for safety concerns [sec · filed 2026-03-31].
- Product development risk — No assurance that any product candidate will be safe, effective, or obtain regulatory approval [sec · filed 2026-03-31].
- Financing and dilution risk — Future capital may cause dilution or require relinquishing rights to product candidates [sec · filed 2025-04-28].
What to watch
- Progress of the ANGELICA Trial and any termination notices from National University Hospital Singapore [sec · filed 2026-03-31].
- Initiation of clinical development for CTM-N2D, iPSC-gdNKT, CTM-GDT, CTM-MSC, and CTM-NK [sec · filed 2026-03-31].
- Ability to secure additional financing and its terms (equity or debt) [sec · filed 2025-04-28].
- Any updates on the cGMP facility's validation and commercial-scale production capabilities [sec · filed 2026-03-31].
Sources: SEC filings · Generated October 1, 2026 · How we verify sources →
Run CytoMed Therapeutics Ltd through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CytoMed Therapeutics Ltd facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.17
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
3 buys · 0 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$16K
| Holder | Shares | Value |
|---|---|---|
| xtx topco ltd | 10,136 | $10K |
| ubs group ag | 6,182 | $6K |
| osaic holdings, inc. | 21 | $21 |
Short Interest
as of Apr 21, 2026- % of float
- 2.4%
- Days to cover
- 8.2
- Shares short
- 82,681
- Daily short volume (Oct 13, 2026)
- 17.2%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GDTC short interestFrequently asked questions
What is the AI investment thesis for CytoMed Therapeutics Ltd?
CytoMed Therapeutics Ltd (GDTC) is a clinical-stage biopharmaceutical company headquartered in Singapore, focused on developing allogeneic immune cell-based cancer therapies and mesenchymal stem cell (MSC) treatments for degenerative diseases, with production facilities in Malaysia.
Where is CytoMed Therapeutics Ltd headquartered?
CytoMed Therapeutics Ltd (GDTC) is headquartered in Singapore, Singapore.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.